Bioshares has introduced a new Corporate Subscription product.
By subscribing to this new service, listed biotech companies
can ensure secured research and analysis of their companies
in the biotech investment publication, and importantly,
this will remain an independent service.
As the number of biotech companies listed
on the ASX has expanded from less than 30 in 1999 to over
120 today, it is becoming increasingly difficult to provide
comprehensive and timely analysis of this sector under the
current structure. Over the last six years, the Bioshares
service has been funded predominantly by retail investors
seeking assistance with their biotech investment decisions.
To ensure the viability of the Bioshares research service
into the future, we have introduced this new corporate service.
more comprehensive analysis
The new research fee structure will provide a number of
benefits to investors and listed biotech companies. Investors
who subscribe to Bioshares will receive wider and more comprehensive
coverage of the biotech sector for no additional cost, and
also coverage of companies that have received limited analysis
by Bioshares to date. Biotech companies can lock in regular
independent analysis by the Bioshares team and Corporate
Subscribers will immediately gain copyright access to any
articles covering their company.
Specifically, Bioshares Corporate Subscribers
· One major analysis each year, between but not limited
to 1200 – 1500 words
· Two updates each year, between 600 – 800
words in length each
· Immediate copyright access to all Bioshares articles
that feature the subscribing company in a PDF extract format
· Distribution of weekly Bioshares for up to 5 employees
and directors for 12 months
established and will be maintained
Our independence has been established and acknowledged over
the last six years through publishing what we believe is
a widely respected investment newsletter. Independence remains
crucial to our objectives in providing accurate investment
advise to subscribers and we are confident our independence
will be retained after the introduction of this new product.
It is also important to maintain this independence for the
biotech companies we follow, as we believe the analysis
in Bioshares will continue to be respected and well received
by institutional and retail investors.
By ‘secured’ we mean that
companies will get under the spotlight of Bioshares. What
is does not mean is that companies can tell Bioshares what
to write and when to write it.
and conditions & subscription
To accept this offer, companies will be required accept
set terms and conditions, acknowledging that Bioshares maintains
full analysis independence and that we can and will place
a Buy, Hold or Sell recommendations on a particular stock
reflecting the results from our company research. The terms
and conditions of this service form can be viewed on the
companies will still be covered
The Bioshares view on many companies in the sector has been
recorded and is well known to most readers. Don’t
expect our frank and forthright views to change. We will
also continue to cover companies that do not subscribe to
this new service. And we will list the companies on the
rear page of each edition that have become Corporate Subscribers.